Literature DB >> 11226633

Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects.

J Liepert1, S Schardt, C Weiller.   

Abstract

Oral application of atropine was used to test if a modulation of cholinergic neurotransmission changed motor excitability. Healthy volunteers received either 1 or 2 mg atropine. Paired transcranial magnetic stimulation was used to study intracortical inhibition and intracortical facilitation before, 1 h and 24 h after ingestion of atropine. In addition, the silent period, motor threshold, F wave and motor response amplitudes were measured. The 1 mg dose of atropine induced a loss of intracortical inhibition, the 2 mg dose produced an intracortical disinhibition and enhanced intracortical facilitation. These changes returned to baseline after 24 h. Other electrophysiological parameters remained unchanged. Thus, an antagonist of pre- and postsynaptic muscarinic receptors increased excitability in the human motor cortex in a dose-dependent manner, indicating an influence of the cholinergic system on motor cortex excitation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226633     DOI: 10.1016/s0304-3940(01)01572-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

Review 1.  Modulation of motor cortex excitability by sustained peripheral stimulation: the interaction between the motor cortex and the cerebellum.

Authors:  Andreas R Luft; Mario-Ubaldo Manto; Nordeyn Oulad Ben Taib
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

2.  Modification of motor cortical excitability by an acetylcholinesterase inhibitor.

Authors:  Alexei Korchounov; Tihomir V Ilic; Tilo Schwinge; Ulf Ziemann
Journal:  Exp Brain Res       Date:  2005-07-01       Impact factor: 1.972

3.  Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse.

Authors:  Thomas Wobrock; Alkomiet Hasan; Berend Malchow; Claus Wolff-Menzler; Birgit Guse; Nicolas Lang; Thomas Schneider-Axmann; Ullrich K H Ecker; Peter Falkai
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

4.  Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI).

Authors:  Peter Eichhammer; Berthold Langguth; Rainer Wiegand; Alexander Kharraz; Ulrich Frick; Göran Hajak
Journal:  Psychopharmacology (Berl)       Date:  2003-02-01       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.